Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

Completed · Phase 3 · Has a placebo group

Conditions studied: Irritable Bowel Syndrome With Diarrhea

In brief

The purpose of the study is to determine the efficacy and safety of Rezular (arverapamil) in the treatment of IBS-D.

Key facts

Study ID

NCT00552565

Run by

AGI Therapeutics, Inc.

People needed

711

Starts

2007-09-01

Expected to finish

2009-06-01

Last updated by the study team

2009-06-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• fulfilling Rome III criteria for IBS-D

You may not qualify if…

• major cardiovascular disease
• psychiatric illness except mild or moderate depression
• pregnancy
• presence of other GI disease that could explain IBS-like symptoms
• history of major gastric, hepatic, pancreatic or intestinal surgery or perforation

Where it is running

• PPD — Wilmington, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.